Chen Jihua, Garlits John, Dhulipala Gangadhar, Sirimanne Thanoja, Xu Colleen, Lu Kun, Palackal Nisha, Pyles Erica, Torri Albert, Sumner Giane
Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.
Bioanalysis. 2019 Sep;11(17):1569-1580. doi: 10.4155/bio-2018-0187. Epub 2019 Jun 18.
Soluble drug target in clinical study samples generated false positive results in anti-drug antibody (ADA) bridging assays due to target-mediated bridging. The combination of two target-blocking reagents and mild basic assay pH resulted in high tolerance to recombinant target protein and reduced levels of positivity in clinical study samples with pharmacokinetic profiles that did not indicate significant ADA response. Testing with low-affinity ADA positive serum from immunized rabbits and known ADA positive samples from nonclinical studies in rats confirmed the assay's ability to detect ADA positive samples and the minimal impact of basic pH and target-blocking reagents on ADA detection. These strategies provide alternatives for mitigating target interference when standard target-blocking antibodies alone are ineffective.
临床研究样本中的可溶性药物靶点由于靶点介导的桥接作用,在抗药物抗体(ADA)桥接试验中产生了假阳性结果。两种靶点阻断试剂与温和碱性的检测pH值相结合,使得对重组靶点蛋白具有高耐受性,并降低了临床研究样本中的阳性水平,这些样本的药代动力学特征并未表明有显著的ADA反应。用免疫兔子的低亲和力ADA阳性血清以及大鼠非临床研究中的已知ADA阳性样本进行检测,证实了该试验检测ADA阳性样本的能力,以及碱性pH值和靶点阻断试剂对ADA检测的最小影响。当单独使用标准的靶点阻断抗体无效时,这些策略为减轻靶点干扰提供了替代方法。